Will CROs Take On the Risks of Strategic Outsourcing?

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-06-02-2004
Volume 28
Issue 6

It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.

External Link - article-98054.pdf

Articles in this issue
Microbial Testing in Support of Aseptic Processing
June 2004
Uniformity of Bioprocessing Equipment Manufacturing
Research Tips To Find Packaging Facts Fast
New Technologies Optimize Biotech Process Efficiency
Will CROs Take On the Risks of Strategic Outsourcing?
Battles Escalate Over Prescription Drug Imports
USP's Semi-Hemiquinquennial Meeting
In the Spotlight - June 2004
Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Feliza Mirasol
March 18th 2025
Article

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025

Patrick Lavery
March 17th 2025
Article

This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

CordenPharma and Viking Therapeutics to Partner for Integrated Supply of GLP-1s

Patrick Lavery
March 13th 2025
Article

The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New Almac Pharma Services Commercial Manufacturing Facility Opens in Northern Ireland

Patrick Lavery
March 11th 2025
Article

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.